

PAH STOPS AT NOTHING. ASKING YOUR DOCTOR ABOUT TREATMENT OPTIONS STARTS WITH YOU.

Uptravi
selexipag
tablets 200-1600 mg



Learn more about a comprehensive treatment plan that includes UPTRAVI® to discover if there are any new angles you can explore with your doctor to help delay PAH progression.

QUESTIONS YOU MAY WANT TO ASK YOUR DOCTOR

- Are there angles that I have not explored to help delay my PAH progression?
- Are my PAH medications targeting the prostacyclin pathway?
- Can UPTRAVI® help me delay the risk of disease progression?
- Can UPTRAVI® work in combination with other PAH treatments?
- Was UPTRAVI® proven to be effective in a clinical trial?

What is UPTRAVI®?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI® is safe and effective in children.

IMPORTANT SAFETY INFORMATION



- **Do not take UPTRAVI® if you** take gemfibrozil because this medicine may affect how UPTRAVI® works and cause side effects
- **Do not take UPTRAVI® if you** are allergic to selexipag or any of the ingredients in UPTRAVI®

See additional Important Safety Information below.



SUPPORT FOR PATIENTS AND THEIR CAREGIVERS

Once you and your healthcare provider have decided that UPTRAVI® is right for you, Janssen CarePath will help you find the resources you may need to get started and stay on track. We will give you information on your insurance coverage, potential out-of-pocket costs, and treatment support, and identify options that may help make your treatment more affordable.

Visit [JanssenCarePath.com/UPTRAVI](https://www.JanssenCarePath.com/UPTRAVI).

Need Help? Call a Janssen CarePath Care Coordinator at 866-228-3546, Monday-Friday, 8:00 am to 8:00 am ET. Multilingual phone support is available.

If you use commercial or private health insurance to pay for your medication:
Janssen CarePath Oral PAH Savings Program for UPTRAVI®

Eligible patients using commercial or private insurance can save on out-of-pocket medication costs for UPTRAVI®. Eligible patients **pay \$5 per prescription fill** with a \$20,000 maximum program benefit per calendar year across all oral PAH therapies in the program. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement.

See full eligibility requirements at [UPTRAVI.JanssenCarePathSavings.com](https://www.UPTRAVI.JanssenCarePathSavings.com).

If you use a government-funded healthcare program to pay for UPTRAVI® or have no insurance coverage and need help paying for your medication:

Janssen CarePath can provide information about other resources that may be able to help with your out-of-pocket medication costs for UPTRAVI®.

Call a Janssen CarePath Care Coordinator at **866-228-3546** or visit [JanssenCarePath.com](https://www.JanssenCarePath.com) for more information about affordability programs and independent foundations[†] that may have funding available.

[†]Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. This information is provided as a resource for you. We do not endorse any particular foundation.

IMPORTANT SAFETY INFORMATION (CONTINUED)

- **Before you take UPTRAVI[®], tell your healthcare provider about all your medical conditions, including if you:**

- Have liver problems
- Have narrowing of the pulmonary veins (veins in your lungs). This is called pulmonary veno-occlusive disease (PVOD)
- Are pregnant or plan to become pregnant. It is not known if UPTRAVI[®] will harm your unborn baby
- Are breastfeeding or plan to breastfeed. It is not known if UPTRAVI[®] passes into your breast milk. You and your doctor should decide if you will take UPTRAVI[®] or breastfeed. You should not do both
- Are taking any other prescription or over-the-counter medicines, vitamins, or herbal supplements

What are the possible side effects of UPTRAVI[®]?



The most common side effects are:

- Headache
- Diarrhea
- Jaw pain
- Nausea
- Muscle pain
- Vomiting
- Pain, redness or swelling at the injection site with UPTRAVI[®] for injection
- Pain in arms or legs
- Temporary reddening of the skin (flushing)
- Joint pain
- Low red blood cell count
- Less appetite than usual
- Rash

Talk to your doctor if you have a side effect that bothers you or does not go away. These are not all the possible side effects of UPTRAVI[®]. For more information, ask your doctor or pharmacist.

You may report side effects to **FDA at 1-800-FDA-1088 or www.fda.gov/medwatch**.

Keep UPTRAVI[®] and all other medicines away from children.

What other medicines might interact with UPTRAVI[®]?



UPTRAVI[®] and other medicines may affect each other, causing side effects. Tell your doctor about all the medicines you are taking. Do not start any new medicine until you check with your doctor.

How should I take UPTRAVI[®]?



UPTRAVI[®] Tablets

- Take UPTRAVI[®] exactly as your doctor tells you to take it. Usually, your doctor will have you take UPTRAVI[®] twice a day. Taking UPTRAVI[®] with food may help you tolerate UPTRAVI[®] better
- Swallow UPTRAVI[®] tablets whole. Do not split, crush, or chew tablets
- Tell your doctor if you have any form of liver disease. Your doctor may need to change your dose of UPTRAVI[®]
- UPTRAVI[®] is measured in micrograms (mcg). Tablets come in the following strengths: 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg

UPTRAVI[®] given by intravenous (IV) injection

- Your healthcare provider will give you UPTRAVI[®] into your vein through an intravenous (IV) line
- Your healthcare provider will decide how much UPTRAVI[®] for injection you will receive each day based on your current dose of UPTRAVI[®] tablets

Please see full [Prescribing Information](#) and [Patient Product Information](#).

cp-113991v5

©2021 Actelion Pharmaceuticals US, Inc. All rights reserved. 11/21 cp-134436v3